Literature DB >> 22814405

Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells.

Amelie Croset1, Laurence Delafosse, Jean-Philippe Gaudry, Christian Arod, Loic Glez, Christophe Losberger, Damien Begue, Ana Krstanovic, Flavie Robert, Francis Vilbois, Laurent Chevalet, Bruno Antonsson.   

Abstract

Glycosylation is one of the most common posttranslational modifications of proteins. It has important roles for protein structure, stability and functions. In vivo the glycostructures influence pharmacokinetics and immunogenecity. It is well known that significant differences in glycosylation and glycostructures exist between recombinant proteins expressed in mammalian, yeast and insect cells. However, differences in protein glycosylation between different mammalian cell lines are much less well known. In order to examine differences in glycosylation in mammalian cells we have expressed 12 proteins in the two commonly used cell lines HEK and CHO. The cells were transiently transfected, and the expressed proteins were purified. To identify differences in glycosylation the proteins were analyzed on SDS-PAGE, isoelectric focusing (IEF), mass spectrometry and released glycans on capillary gel electrophoresis (CGE-LIF). For all proteins significant differences in the glycosylation were detected. The proteins migrated differently on SDS-PAGE, had different isoform patterns on IEF, showed different mass peak distributions on mass spectrometry and showed differences in the glycostructures detected in CGE. In order to verify that differences detected were attributed to glycosylation the proteins were treated with deglycosylating enzymes. Although, culture conditions induced minor changes in the glycosylation the major differences were between the two cell lines.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814405     DOI: 10.1016/j.jbiotec.2012.06.038

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  56 in total

1.  Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.

Authors:  Changming Yu; Gennett M Pike; Tommy A Rinkoski; Cristina Correia; Scott H Kaufmann; Mark J Federspiel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

2.  Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.

Authors:  Pilarin Nichols; Li Li; Sandeep Kumar; Patrick M Buck; Satish K Singh; Sumit Goswami; Bryan Balthazor; Tami R Conley; David Sek; Martin J Allen
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 3.  Using glyco-engineering to produce therapeutic proteins.

Authors:  Martina Dicker; Richard Strasser
Journal:  Expert Opin Biol Ther       Date:  2015-07-14       Impact factor: 4.388

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

5.  Recent advances in the analysis of therapeutic proteins by capillary and microchip electrophoresis.

Authors:  Jessica S Creamer; Nathan J Oborny; Susan M Lunte
Journal:  Anal Methods       Date:  2014-07-08       Impact factor: 2.896

6.  Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease.

Authors:  Xiaotian Zhong; Srinath Jagarlapudi; Yan Weng; Mellisa Ly; Jason C Rouse; Kim McClure; Tetsuya Ishino; Yan Zhang; Eric Sousa; Justin Cohen; Boriana Tzvetkova; Kaffa Cote; John J Scarcelli; Keith Johnson; Joe Palandra; James R Apgar; Suma Yaddanapudi; Romer A Gonzalez-Villalobos; Alan C Opsahl; Khetemenee Lam; Qing Yao; Weili Duan; Annette Sievers; Jing Zhou; Darren Ferguson; Aaron D'Antona; Richard Zollner; Hongli L Zhu; Ron Kriz; Laura Lin; Valerie Clerin
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

7.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Molecular and Functional Characterization of Fcγ Receptor IIIb-Ligand Interaction: Implications for Neutrophil-Mediated Immune Mechanisms in Malaria.

Authors:  Ulrich J Sachs; Sentot Santoso; Piyapong Simtong; Amornrat V Romphruk; Annalena Traum; Monika Burg-Roderfeld; Gregor Bein; Konstantin Jakubowski; Andreas Dominik; Michael Theisen; Ikhlaq Hussain Kana
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

9.  Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.

Authors:  Stefan Michelfelder; Juliana Parsons; Lennard L Bohlender; Sebastian N W Hoernstein; Holger Niederkrüger; Andreas Busch; Nicola Krieghoff; Jonas Koch; Benjamin Fode; Andreas Schaaf; Thomas Frischmuth; Martin Pohl; Peter F Zipfel; Ralf Reski; Eva L Decker; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

10.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.